Chimeric Therapeutics Ltd (ASX:CHM) CEO and managing director Jennifer Chow speaks with Andrew Scott from Proactive about entering into a sponsored research agreement (SRA) with Case Western Reserve University (CWRU) to further advance its NK cell therapy portfolio. The program will be led by Dr David Wald. Chow discusses the program's development progress and provides information on the second clinical trial.
Chimeric Therapeutics outlines sponsored research agreement to advance NK cell therapy portfolio
